Neuralink N1/R1: the PRIME clinical study

PRIME (NCT06429735) is one early-feasibility study within Neuralink’s broader N1/R1 programme, not the whole brain-computer-interface field. It studies initial device safety and functionality in people with severe paralysis. The intended benefit is control of external devices, not proven restoration of natural limb movement or general cognitive enhancement.

The N1 design described on 2024-04-12 has 1024 electrodes on 64 flexible threads, inserted into the cortex by the R1 robot. Electronics process neural signals and transmit them wirelessly to software that decodes commands such as cursor movement; an implanted battery is recharged inductively. The 2019 paper instead describes a preclinical research platform, including a 3072-channel configuration tested in rats. It is not the human N1 specification. Electrode count alone does not measure usable information, independence or clinical benefit.

The registry consulted on 2026-09-14 lists an open-label, single-group device-feasibility study, with 15 participants estimated, not a confirmed enrolled total. Primary outcomes concern device- and procedure-related adverse events at 12 months; secondary safety follow-up extends to 72 months after implantation. Without a comparison group, this design does not establish comparative efficacy.

Neuralink reported first human implantation in January 2024 and subsequent computer control. On 2026-01-28 it reported 21 participants across trials worldwide, not 21 participants confirmed in this PRIME record. These developer reports describe use, not an independently replicated clinical assessment. The PRIME registry still displays no results posted. That does not mean no results exist elsewhere, and it does not invalidate the reported demonstrations.

In May 2024 Neuralink reported thread retraction, fewer effective electrodes and reduced cursor performance in the first participant; software changes were reported to improve performance. In January 2026 it still described variability between participants and work on thread retention and surgical procedures. These reports do not establish long-term safety or a reliable population-wide benefit. Absence of posted registry results cannot be treated as proof of safety.

Neuralink Corp sponsors PRIME and develops the device. The registry lists Barrow Neurological Institute in Phoenix and University of Miami in Miami as US study sites, with Francisco Ponce and Jonathan Jagid respectively as principal investigators. Clinical teams and participants contribute the procedures, use and follow-up; their work is not attributed to a company executive. A verified PRIME-specific budget, expenditure total and cost per participant are not available in the sources reviewed.

The registry gives 2024-01-09 as the actual study start, distinct from the developer’s January 2024 implantation announcement and the registry’s first posting on 2024-05-28. Its last posted update is 2026-01-09. Primary completion remains estimated at June 2026 and study completion at January 2031. The June 2026 estimate is now past; the registry still says recruiting. This documentary mismatch does not establish completion, abandonment or clinical failure. Roadmap positions are ordinal, not a time-to-completion scale.

Scope: N1/R1 with emphasis on US PRIME; international trials and other applications are not merged into one population. In January 2026 Neuralink announced work toward increasing electrode count from approximately 1000 to 3000; this is not evidence that an upgraded implant has been delivered. A general bidirectional interface is a broader ambition, not PRIME’s demonstrated outcome. Next checks: registry revisions, cohort-specific results, adverse-event follow-up and documented hardware changes.